Joint Committee Opinion 27/2020 on criteria and restrictions for senior staff applying for occupational activities within two years after leaving the Agency

Establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation

Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application

Guidance for competent authorities on how to highlight VNRAs

Agenda of the CHMP meeting 16-19 September 2024

Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Date of authorisation: 23/02/2004, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Bondronat, ibandronic acid, Date of authorisation: 25/06/1996, Revision: 34, Status: Authorised

IRIS guide for applicants - How to create and submit scientific applications, for industry and individual applicants

Early dialogue with healthcare professional organisations for marketing authorisation applications: 1-year report

Opinion/decision on a Paediatric investigation plan (PIP): Uplizna, Inebilizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0513/2023